Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer (Q83774542)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

title

Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

1 reference

antineoplastic resistance

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

29 November 2024

author name string

Gina Mantia-Smaldone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

Esther Elishaev

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

Tianjiao Chu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

Julia Thaller

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

Kathryn McCabe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

Diana Lenzner

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

Raluca A. Budiu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

29 November 2024

Robert P. Edwards

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

29 November 2024

Anda M. Vlad

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

29 November 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21461842

29 November 2024

publication date

2 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

full work available at URL

27 January 2020

https://europepmc.org/articles/PMC11029120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

https://europepmc.org/articles/PMC11029120?pdf=render

29 November 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

https://doi.org/10.1007/s00262-011-1010-x

29 November 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21461842

http://link.springer.com/content/pdf/10.1007/s00262-011-1010-x.pdf

29 November 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

http://link.springer.com/article/10.1007/s00262-011-1010-x/fulltext.html

29 November 2024

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

http://link.springer.com/content/pdf/10.1007/s00262-011-1010-x

29 November 2024

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Cancer Immunology, Immunotherapy

29 November 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

975-984

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

Reactivity of a monoclonal antibody with human ovarian carcinoma

27 January 2020

cites work

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1172/JCI110380

Achievements and unmet needs in the management of advanced ovarian cancer

1

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Mucins in cancer: function, prognosis and therapy

29 November 2024

2

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

MUC1 immunobiology: from discovery to clinical applications

29 November 2024

3

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

29 November 2024

4

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction

29 November 2024

5

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125)

29 November 2024

6

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer

29 November 2024

8

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients

29 November 2024

9

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

29 November 2024

10

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer

29 November 2024

11

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer

29 November 2024

13

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Potential markers that complement expression of CA125 in epithelial ovarian cancer

29 November 2024

14

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

The CA 125 tumour-associated antigen: a review of the literature

29 November 2024

15

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Validation of tissue microarray technology in ovarian carcinoma

29 November 2024

16

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer

29 November 2024

17

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer

29 November 2024

18

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer

29 November 2024

19

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss

29 November 2024

20

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival

29 November 2024

21

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8 /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

29 November 2024

22

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

A systematic review of humoral immune responses against tumor antigens

29 November 2024

23

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Treatment of metastatic melanoma with autologous CD4 T cells against NY-ESO-1

29 November 2024

25

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis

29 November 2024

26

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Antigen-specific interaction between T and B cells

29 November 2024

27

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors

29 November 2024

28

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

29 November 2024

The Th1/Th2 paradigm

30

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

29 November 2024

31

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis

29 November 2024

32

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

29 November 2024

34

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

29 November 2024

35

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer

29 November 2024

36

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

29 November 2024

37

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer

29 November 2024

38

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer

29 November 2024

39

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

29 November 2024

40

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

29 November 2024

41

1 reference

https://api.crossref.org/works/10.1007/S00262-011-1010-X

29 November 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21461842 AND SRC:MED&resulttype=core&format=json

Dimensions Publication ID

27 January 2020

0 references

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21461842

29 November 2024

1 reference